title: State and trait markers of emotionally charged visual event-related potentials (P300) in drug-naïve schizophrenia.
abstract: OBJECTIVE
  In the present study, we investigated the changes in P3 component in the emotionally charged visual event-related potentials (ERP) in 30 drug-naïve schizophrenic patients for up to 1 year.
  
  
  METHODS
  Visual oddball event-related potential was recorded from six recording sites for crying baby or smiling baby photographs. ERP were recorded before the treatment (session 1 [S1]), after 3 months (session 2 [S2]), and after 12 months (session 3 [S3]), as well as in 30 healthy subjects.
  
  
  RESULTS
  Before taking medicine, there were no significant differences in the P300 amplitude between viewing photographs of a crying and a smiling baby. The P300 amplitude was significantly larger at S2 and S3 than at S1 for a crying baby, while there was no significant difference among sessions for a smiling baby after medication. A significant difference of the P300 amplitude was only observed between S3 and healthy subjects for a smiling baby. The P300 latency only when viewing a smiling face became significantly longer at S3 than those at S1 and S2. A significant negative correlation was obtained between the P300 amplitude changes upon viewing crying faces and negative syndrome score changes at the Pz site.
  
  
  CONCLUSIONS
  The P300 amplitude induced by crying-face stimuli may be a state marker and the P300 amplitude caused by smiling-face stimuli may be a trait marker during recovery in schizophrenic patients. Atypical antipsychotic medications may be useful and may recover cognitive function reflected by the emotionally charged visual P300 components in schizophrenic patients.
authors.affiliation: Department of Neuropsychiatry, Kurume University School of Medicine, Kurume, Japan.
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Mori
authors.forename: Kiichiro
authors.initials: K
authors.lastname: Morita
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Shoji
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Matsuoka
authors.forename: Ryo
authors.initials: R
authors.lastname: Fujiki
authors.forename: Naohisa
authors.initials: N
authors.lastname: Uchimura
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000494:pharmacology / Q000627:therapeutic use; D016022:Case-Control Studies; D004644:Emotions / Q000187:drug effects / Q000502:physiology*; D018913:Event-Related Potentials, P300 / Q000187:drug effects / Q000502:physiology*; D005074:Evoked Potentials, Visual / Q000187:drug effects / Q000502:physiology*; D005149:Facial Expression; D005260:Female; D006801:Humans; D054833:Isoindoles / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D000077152:Olanzapine; D010775:Photic Stimulation / Q000379:methods; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D018967:Risperidone / Q000494:pharmacology / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D054833:Isoindoles; D013844:Thiazoles; D001569:Benzodiazepines; D018967:Risperidone; C065533:perospirone; D000077152:Olanzapine